Cours suspendu

Communiqués Avidity Biosciences, Inc.

Actions

RNA

US05370A1088

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/02/2026			Varia. 5j.	Varia. 1 janv.
72,82 ^USD	+0,03%		-.--%	+0,96%

06/08	AVIDITY BIOSCIENCES, INC. : HC Wainwright toujours positif	ZM
14/07	Atrium Therapeutics : la FDA autorise un essai de phase 1/2 pour l'ATR 1072 dans le syndrome PRKAG2	MT

Communiqués

02/03	Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies	AQ
02/03	Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy	AQ
27/02	Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies	PR
26/02	Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference	PR
23/02	Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders	PR
18/02	The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1	PR
03/02	Avidity Biosciences Announces Expected Record Date for Spin-Off	PR
20/11	Pharma giant Novartis aims for strong growth thanks to cancer treatments	AQ
20/11	Avidity Biosciences Announces U.S. Managed Access Program for Investigational Therapy del-zota in DMD44	AQ
19/11	Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44	PR
10/11	Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights	PR
28/10/25	Avidity Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avidity Biosciences, Inc. - RNA	BU
27/10/25	Novartis acquires Avidity Biosciences for $12 billion	AQ
27/10/25	Novartis strengthens neuroscience pipeline with $12bn Avidity acquisition	AQ
26/10/25	Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG	PR
16/10/25	Avidity Biosciences to Participate in Upcoming Investor Conference	PR
13/10/25	Avidity Biosciences : October 2025 Corporate Presentation	PU
13/10/25	Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026	PR
06/10/25	Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society	PR
15/09/25	Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares	PR
12/09/25	Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock	PR
10/09/25	Avidity Biosciences Announces Proposed Public Offering of Common Stock	PR
10/09/25	Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44	PR
27/08/25	Avidity Biosciences to Participate in Upcoming Investor Conferences	PR
07/08/25	Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights	PR